logo

Clearside Biomedical, Inc. (CLSD)



Trade CLSD now with
  Date
  Headline
12/6/2017 12:03:10 PM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) FY18 Estimate To -2.37 From -2.59
12/6/2017 12:02:36 PM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q4 18 Estimate To -0.67 From -0.70
12/6/2017 12:02:13 PM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q3 18 Estimate To -0.57 From -0.66
12/6/2017 12:01:51 PM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q2 18 Estimate To -0.56 From -0.63
12/6/2017 11:52:37 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q1 18 Estimate To -0.56 From -0.61
12/6/2017 11:52:16 AM Wedbush Is Lowering Clearside Biomedical, Inc. (CLSD) FY17 Estimate To -2.24 From -2.06
12/6/2017 11:51:46 AM Wedbush Is Lowering Clearside Biomedical, Inc. (CLSD) Q4 17 Estimate To -0.57 From -0.56
12/6/2017 11:51:14 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $27 Price Target
11/13/2017 7:40:18 AM Clearside's Phase 1/2 Open Label Clinical Trial Of CLS-TA With And Without Eylea In Diabetic Macular Edema Presented
11/8/2017 7:14:26 AM Clearside Biomedical Q3 Net Loss $18.3 Mln Or $0.72/Shr Vs Loss $5.6 Mln Or $0.28/Shr Last Year
8/25/2017 9:05:56 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $27 Price Target
8/9/2017 7:23:24 AM Clearside Biomedical Q2 Net Loss $13.8 Mln Or $0.54/shr Vs. Net Loss $5.1 Mln Or $0.62/shr Last Year
8/7/2017 8:16:27 AM Clearside Biomedical Completes Patient Enrollment In Pivotal Phase 3 PEACHTREE Clinical Trial Of CLS-TA
6/8/2017 1:01:55 AM Clearside Biomedical Presents ANZANITE Extension Study In Patients With Macular Edema Associated With RVO
5/10/2017 7:23:17 AM Clearside Biomedical Q1 Net Loss $10.4 Mln Or $0.41/shr Vs Loss $5.4 Mln Or $2.05/shr Last Year